MA43567A - Anticorps pacap et leurs utilisations - Google Patents
Anticorps pacap et leurs utilisationsInfo
- Publication number
- MA43567A MA43567A MA043567A MA43567A MA43567A MA 43567 A MA43567 A MA 43567A MA 043567 A MA043567 A MA 043567A MA 43567 A MA43567 A MA 43567A MA 43567 A MA43567 A MA 43567A
- Authority
- MA
- Morocco
- Prior art keywords
- pacap antibodies
- pacap
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562267822P | 2015-12-15 | 2015-12-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA43567A true MA43567A (fr) | 2018-11-14 |
Family
ID=57708866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA043567A MA43567A (fr) | 2015-12-15 | 2016-12-15 | Anticorps pacap et leurs utilisations |
Country Status (4)
Country | Link |
---|---|
US (2) | US10822408B2 (fr) |
EP (1) | EP3390447A1 (fr) |
MA (1) | MA43567A (fr) |
WO (1) | WO2017106578A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106459990B (zh) | 2014-02-07 | 2021-06-01 | 麦克马斯特大学 | 三功能t细胞抗原偶联物及其制备方法和用途 |
EP3283169A4 (fr) | 2015-04-16 | 2019-03-20 | Alder Biopharmaceuticals, Inc. | Utilisation d'anticorps anti-pacap et de leurs fragments de liaison à l'antigène pour le traitement, la prévention ou l'inhibition de la photophobie |
EP3390447A1 (fr) | 2015-12-15 | 2018-10-24 | Amgen Inc. | Anticorps pacap et leurs utilisations |
CN109451728A (zh) | 2016-04-15 | 2019-03-08 | 奥尔德生物制药公司 | 抗pacap抗体及其用途 |
AR113022A1 (es) * | 2017-09-29 | 2020-01-15 | Lilly Co Eli | Anticuerpo anti-pacap |
AU2018349093A1 (en) | 2017-10-12 | 2020-05-28 | Mcmaster University | T cell-antigen coupler with Y182T mutation and methods and uses thereof |
AU2019207915A1 (en) | 2018-01-12 | 2020-07-16 | Amgen Inc. | PAC1 antibodies and uses thereof |
US11110123B2 (en) | 2018-07-17 | 2021-09-07 | Triumvira Immunologics Usa, Inc. | T cell-antigen coupler with various construct optimizations |
US20220363770A1 (en) | 2019-06-28 | 2022-11-17 | Amgen Inc. | Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins |
WO2021150910A1 (fr) * | 2020-01-23 | 2021-07-29 | Ubi Ip Holdings | Immunogènes peptidiques ciblant le peptide d'activation d'adénylate cyclase pituitaire (pacap) et formulations associées pour la prévention et le traitement de la migraine |
US11453723B1 (en) | 2021-06-25 | 2022-09-27 | Mcmaster University | BCMA T cell-antigen couplers and uses thereof |
AR126603A1 (es) * | 2021-07-29 | 2023-10-25 | Cephalon Llc | Composiciones y métodos para anticuerpos anti-pacap |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
EP0435911B1 (fr) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Milieu de culture de cellules pour l'amelioration de la croissance des cellules, de la longivite de la culture et de l'expression du produit |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
WO1990005183A1 (fr) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Recepteurs d'interleukine-4 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
US5486472A (en) | 1990-03-17 | 1996-01-23 | Takeda Chemical Industries, Ltd. | Monoclonal antibodies to PACAP |
WO1991018982A1 (fr) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Recepteurs de l'interleukine-1 de type ii |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0546073B1 (fr) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production et utilisation des animaux non humains transgeniques capable de produire des anticorps heterologues |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
EP0652950B1 (fr) | 1992-07-24 | 2007-12-19 | Amgen Fremont Inc. | Production d'anticorps xenogeniques |
EP0618291A3 (fr) | 1993-02-26 | 1997-12-03 | Takeda Chemical Industries, Ltd. | Protéine réceptrice-PACAP, méthode pour la préparation de cette protéine et l'utilisation de celle-ci |
US6399316B1 (en) | 1994-02-25 | 2002-06-04 | Takeda Chemical Industries, Ltd. | PACAP receptor protein, method for preparing said protein, and use thereof |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク. | 免疫したゼノマウス(XenoMouse)に由来するヒト抗体 |
US6462016B1 (en) | 1995-10-06 | 2002-10-08 | Shiseido Company, Ltd. | Method for screening agonist or antagonist of the maxadilan receptor participating in vasodilating action, and compound found by the method |
CA2249195A1 (fr) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Domaines analogues a l'immunoglobuline a demi-vies prolongees |
US6017533A (en) | 1996-04-25 | 2000-01-25 | Shiseido Company, Ltd. | Peptides having specific affinity to pituitary adenylate cyclase activating polypeptide type 1 receptors |
KR100643058B1 (ko) | 1996-12-03 | 2006-11-13 | 아브게닉스, 인크. | 복수의 Vн 및 Vк 영역을 함유하는 인간 면역글로불린 유전자좌를 갖는 트랜스제닉 포유동물 및 이로부터 생성된 항체 |
US6242563B1 (en) | 1998-07-20 | 2001-06-05 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Peptide analogues |
PL345583A1 (en) | 1998-07-20 | 2001-12-17 | Sod Conseils Rech Applic | Peptide analogues of pacap |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US20020155533A1 (en) | 1998-11-30 | 2002-10-24 | Takeda Chemical | PACAP receptor protein, method for preparing said protein, and use thereof |
US20020182729A1 (en) | 2001-01-11 | 2002-12-05 | Dicicco-Bloom Emanuel | Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
WO2004062684A2 (fr) | 2003-01-16 | 2004-07-29 | D. Collen Research Foundation Vzw Onderwijs En Navorsing Campus Gasthuisberg K.U. Leuven | Inhibition de la signalisation pacap dans la prevention et le traitement de la thrombocytopenie |
US20050129687A1 (en) | 2003-11-03 | 2005-06-16 | University Of Vermont And State Agricultural College | Use of inhibitors of PACAP receptor activity for treatment of overactive bladder and pelvic floor pain syndrome |
US20050142133A1 (en) | 2003-12-03 | 2005-06-30 | Xencor, Inc. | Optimized proteins that target the epidermal growth factor receptor |
BRPI0507236A (pt) | 2004-01-30 | 2007-06-26 | Peplin Biolipids Pty Ltd | método para o tratamento ou profilaxia de uma condição, e, composto |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
JP2009506076A (ja) | 2005-08-26 | 2009-02-12 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ | 三叉神経疼痛のための薬物送達のための治療手順 |
CN103073639A (zh) | 2006-03-17 | 2013-05-01 | 比奥根艾迪克Ma公司 | 稳定的多肽组合物 |
EP2048162A4 (fr) | 2006-08-08 | 2010-12-01 | Univ Kyoto | Nouvel anticorps monoclonal et son utilisation |
US8280711B2 (en) | 2007-03-12 | 2012-10-02 | ESBATech, an Alcon Biomedical Research Unit, LLC. | Sequence based engineering and optimization of single chain antibodies |
US8793074B2 (en) | 2007-06-21 | 2014-07-29 | Saint Louis University | Sequence covariance networks, methods and uses therefor |
US20090074780A1 (en) | 2007-06-25 | 2009-03-19 | David Urech | Methods of modifying antibodies, and modified antibodies with improved functional properties |
WO2009033489A2 (fr) | 2007-09-11 | 2009-03-19 | Glostrup Hospital | Traitement de la migraine et de céphalées par des inhibiteurs sélectifs de pac1 |
CN101434649B (zh) | 2008-12-12 | 2012-04-25 | 余榕捷 | 一种环七肽及其制备方法和应用 |
WO2011017122A1 (fr) | 2009-07-27 | 2011-02-10 | Trigemina Inc. | Méthodes de traitement de la douleur |
CA2785139A1 (fr) | 2009-12-22 | 2011-06-30 | Novartis Ag | Proteine hybride tetravalente a region constante d'anticorps anti-cd-47 a utiliser en therapie |
JP5972915B2 (ja) | 2011-03-16 | 2016-08-17 | アムジエン・インコーポレーテツド | Fc変異体 |
EP2794653B1 (fr) | 2011-12-23 | 2019-03-13 | Pfizer Inc | Régions constantes d'anticorps modifiés pour conjugaison spécifique à un site, et leurs procédés et utilisations |
EA201491920A1 (ru) | 2012-05-21 | 2016-03-31 | Дженентек, Инк. | Способы повышения безопасности транспорта через гематоэнцефалический барьер |
US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
EP3283169A4 (fr) | 2015-04-16 | 2019-03-20 | Alder Biopharmaceuticals, Inc. | Utilisation d'anticorps anti-pacap et de leurs fragments de liaison à l'antigène pour le traitement, la prévention ou l'inhibition de la photophobie |
EP3390447A1 (fr) | 2015-12-15 | 2018-10-24 | Amgen Inc. | Anticorps pacap et leurs utilisations |
-
2016
- 2016-12-15 EP EP16820534.2A patent/EP3390447A1/fr active Pending
- 2016-12-15 US US16/063,152 patent/US10822408B2/en active Active
- 2016-12-15 WO PCT/US2016/067054 patent/WO2017106578A1/fr active Application Filing
- 2016-12-15 MA MA043567A patent/MA43567A/fr unknown
-
2020
- 2020-09-24 US US17/031,674 patent/US11780914B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10822408B2 (en) | 2020-11-03 |
US20210095016A1 (en) | 2021-04-01 |
EP3390447A1 (fr) | 2018-10-24 |
US11780914B2 (en) | 2023-10-10 |
US20180362643A1 (en) | 2018-12-20 |
WO2017106578A1 (fr) | 2017-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
MA46708A (fr) | Anticorps anti-pd1 et leurs utilisations | |
MA50618A (fr) | Polyrhérapies et leurs utilisations | |
MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
MA45235A (fr) | Anticorps anti-c5 et leurs utilisations | |
MA49683A (fr) | Anticorps anti-cd8 et leurs utilisations | |
MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
MA43567A (fr) | Anticorps pacap et leurs utilisations | |
MA53184A (fr) | Anticorps anti-ox40 et leurs utilisations | |
MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
MA42935A (fr) | Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations | |
MA49687A (fr) | Anticorps anti-ctla-4 et leurs utilisations | |
MA53400A (fr) | Hétéromultimères alk7: actriib et leurs utilisations | |
MA46471A (fr) | Protéines actriib à variant et leurs utilisations | |
MA43529A (fr) | Modulateurs de transport nucléaire et leurs utilisations | |
MA49886A (fr) | Anticorps anti-par2 et leurs utilisations | |
MA50397A (fr) | Anticorps anti-tau et leurs utilisations | |
MA42622A (fr) | Agents de liaison à tigit et leurs utilisations | |
MA53145A (fr) | Agents de liaison cd123 et leurs utilisations | |
MA45233A (fr) | Anticorps anti-gitr et leurs utilisations | |
MA43821A (fr) | Pyrimidines et variantes de celles-ci, et leurs utilisations | |
MA55044A (fr) | Hétéromultimères alk4:actriib et leurs utilisations | |
MA45690A (fr) | Anticorps anti-tgfb, méthodes et utilisations | |
MA46472A (fr) | Hétéromultimères alk4:actriib et leurs utilisations | |
MA44665A (fr) | Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques |